Last reviewed · How we verify
NCT05175066
Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
Phase 3 trial testing Bisoprolol in Cardiomyopathies in 80 participants. Completed in 2 December 2021.
7 October 2021
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 12 November 2020 |
| Primary completion | 7 October 2021 |
| Estimated completion | 2 December 2021 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Bisoprolol (BISOPROLOL) — full drug profile →
- Placebo
Conditions studied
- Cardiomyopathies — all drugs for Cardiomyopathies →
- Chemotherapy Effect — all drugs for Chemotherapy Effect →
- Diastolic Dysfunction — all drugs for Diastolic Dysfunction →
- Systolic Dysfunction — all drugs for Systolic Dysfunction →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
Adults 35 to 65, female only, with Cardiomyopathies or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart failure. Bisoprlol is a β1-specific β-blocker that can reduce cardiac overload and also have anti-inflammatory antioxidant effects and can reduce reactive oxygen metabolites so it can be used as a cardioprotective agent in patients with a high risk of heart failure. To the best of our knowledge, no study has been performed to evaluate the prophylactic effect of bisoprolol solely in patients under chemotherapy with anthracyclines. This study is aimed to evaluate the cardioprotective role of bisoprolol in patients with non-metastatic breast cancer receiving doxorubicin, by measuring global longitudinal strain before and after treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.
Tetterton-Kellner J, Jensen BC, Nguyen J. · · 2024 · cited 20× · PMID 38901637 · DOI 10.1016/j.addr.2024.115361
Verify or expand the search:
- PubMed search for NCT05175066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bisoprolol
Trials testing the same drug.
- NCT07491718 — Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy · NA · recruiting
- NCT07327749 — Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension · Phase 4 · completed
- NCT05540600 — Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker · Phase 3 · unknown
- NCT05569382 — Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy · Phase 4 · recruiting
- NCT04356196 — Comparative Study Between the Efficacy of Verapamil and Bisoprolol on Reduction of Bleeding During Endoscopic Sinus Surg · EARLY_PHASE1 · unknown
Other recruiting trials for Cardiomyopathies
Currently open trials in the same condition.
- NCT06360939 — Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease · NA · recruiting
- NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
- NCT07006974 — SMCs With LVH Compared to HCM · active not recruiting
- NCT06846086 — Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy · Phase 3 · recruiting
- NCT06978998 — Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in d · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05175066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 3 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing